AI assistant
NYRADA INC. — Major Shareholding Notification 2025
Apr 8, 2025
65469_rns_2025-04-08_51e676a9-3a05-44bf-aae7-d27764756f2d.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
==> picture [596 x 114] intentionally omitted <==
9 April 2025
Sydney, Australia
Notice of Initial Substantial Holder (“Notice”)
Nyrada Inc (ASX: NYR), a drug discovery and development company specialising in innovative Transient Receptor Potential Canonical (TRPC) ion channel blockers, advises further to the Deed Poll dated 6 January 2020 issued by the Company in favour of ASX Limited in respect of the Initial Public Offering of its Chess Depositary Interests (“CDIs”), a Notice of Interests Substantial Holder in relation to Nyrada. Details of the initial interest in CDIs (“Relevant Interests”) are as follows:
Name of Substantial Holder: Mr Mark Azzi
Date of becoming a Substantial Holder : 7 April 2025
Details of voting power of Substantial Holder (through CHESS Depository Nominees Pty Ltd):
| Ltd): | |||
|---|---|---|---|
| Class of Securities | Number of CDIs | Person’s Votes | Voting Power (1) |
| Chess Depositary Interests | 10,814,420 | 10,814,420 | 5.14% |
Present Relevant Interests:
| Present Relevant Interests: | |||
|---|---|---|---|
| Holder of RelevantInterest | Registered Holdings ofCDIs | RelevantInterestNumber ofCDIs | Voting Power(1) |
| Mr Mark Azzi | Mr Mark Azzi | 10,814,420 | 5.14% |
- (1) Based on 210,333,705 CDIs on issue as outlined in Appendix 3H released to ASX on 21 January 2025
NYR has provided a copy of this Notice to Mr Mark Azzi who has confirmed that this document is correct within the meaning of Section 671B of the Corporations Act 2001 (Cth) ( Act ), including the number of equity securities or CDIs disclosed in the Notice, being 10,814,420 CDIs, and that these equity securities represent all equity securities held by the Substantial Shareholder and any associates having a relevant interest within the meaning of Section 608 of the Act.
==> picture [50 x 9] intentionally omitted <==
Page 1
Nyrada Inc. Level 3, 828 Pacific Highway, Gordon NSW 2072
ARBN 625 401 818
==> picture [596 x 114] intentionally omitted <==
About Nyrada Inc
Nyrada Inc. is a biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company’s lead candidate, NYR-BI03, has shown efficacy in both neuroprotection and cardioprotection, positioning it for a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, USA, with limited liability for its stockholders.
www.nyrada.com
Authorised by Mr. James Bonnar, CEO on behalf of the Board.
Investor & Corporate Enquiries: Company Secretary: Dimitri Burshtein David Franks T: 02 9498 3390 T: 02 8072 1400 E: [email protected] E: [email protected]
Forward-Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forwardlooking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.
Page 2
Nyrada Inc. Level 3, 828 Pacific Highway, Gordon NSW 2072
ARBN 625 401 818